GREENBELT, Md., May 12, 2025 — Roddrick Navara Shelby, 48, of Laurel, Maryland, pleaded guilty in federal court to distributing 40 grams or more of fentanyl, U.S. Attorney for the District of Maryland Kelly O. Hayes announced. The plea, revealed alongside Drug Enforcement Administration (DEA) Washington Division Special Agent in Charge Ibrar A. Mian and Montgomery County Police Department (MCPD) Chief Marc R. Yamada, follows an investigation that uncovered Shelby’s sale of over 1,471 fentanyl pills.
The investigation, launched by the DEA and MCPD in November 2024, involved three controlled purchases where Shelby sold approximately 500 fentanyl pills to a confidential source. The blue pills, marked “M30” to mimic legitimate oxycodone hydrochloride, were confirmed by laboratory analysis to contain fentanyl. In total, Shelby distributed more than 150 grams of a fentanyl-containing mixture.
On March 20, 2025, law enforcement executed a search warrant at Shelby’s Laurel residence and vehicle. Authorities found 63 rounds of ammunition, including a loaded magazine, two empty .357 caliber Glock magazines, and one empty .45 caliber Glock magazine, in a kitchen drawer and other areas. Shelby, prohibited from possessing firearms or ammunition due to a prior conviction, also had three digital scales with white residue and three small baggies containing suspected cocaine in the kitchen.
Shelby faces a mandatory minimum sentence of five years in federal prison, with a maximum of 40 years. His sentencing is scheduled for July 15, 2025, at 10 a.m. before a federal judge in Greenbelt.
U.S. Attorney Hayes praised the DEA and MCPD for their investigative efforts and thanked Assistant U.S. Attorneys Megan S. McKoy and Elizabeth Wright for prosecuting the case. The investigation targeted Shelby’s role in fentanyl trafficking, a priority for law enforcement amid the ongoing opioid crisis.
The controlled purchases, conducted under close supervision, revealed Shelby’s distribution of counterfeit pills designed to resemble prescription medication. The “M30” imprint on the pills, typically associated with oxycodone, concealed their fentanyl content, posing significant risks to users unaware of the drug’s potency. Laboratory analysis confirmed the presence of fentanyl, a synthetic opioid linked to numerous overdoses nationwide.
The March 2025 search further exposed Shelby’s illegal activities. The discovery of ammunition, prohibited due to his prior conviction, compounded the charges. The digital scales and suspected cocaine suggest additional drug-related activities, though the plea specifically addresses fentanyl distribution.
Shelby’s guilty plea marks a step in addressing fentanyl trafficking in Maryland, where law enforcement agencies have intensified efforts to disrupt illegal drug networks. The collaboration between the DEA and MCPD exemplifies the multi-agency approach to combating the opioid epidemic, focusing on both street-level distribution and broader supply chains.
The case underscores the dangers of counterfeit pills, which often contain lethal substances like fentanyl. Federal and local authorities continue to prioritize investigations targeting distributors to reduce overdose deaths and protect communities in Montgomery County and beyond. Shelby’s sentencing in July will determine the final consequences of his actions, with prosecutors seeking a penalty reflecting the severity of the offense.
